Analysis of the Risk Factors for the Neutropenic Fever in the High Risk NHL Patients for Developing Febrile Neutropenia Who Received 3-weekly CHOP-like Chemotherapy With Primary G-CSF Prophylaxis; Prospective Multicenter Observation Study
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Yonsei University
With
JW Pharmaceutical
Age
20–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically diagnosed non-Hodgkin's lymphoma patients treated by CHOP-regimen or R (Rituximab)-CHOP regimen at 21±5 days interval
Age \>= 20 years old
The patients with at least one of the following risk factor of neutropenic fever at initiation of anti-cancer treatment
1. Age \>= 65 years old
2. Progressed stage of disease (Ann Arbor stage III)
3. History of previous anti-cancer treatment
4. History of previous radiotherapy (Including bone region includes bone marrow)
5. Bone marrow involvement
6. Comorbid neutropenia (neutrophils \< 1,500/uL ) before the initiation of anti-cancer treatment
7. Comorbid anemia (hemoglobin \< 12.0 g/dL ) before the initiation of anti-cancer treatment
8. Evidence of activated inflammation
9. Existence of open wound
10. Poor health state (ECOG 2)
11. Poor nutritional state (Serum albumin \< 3.5 g/dL)
12. Kidney disease or renal insufficiency
13. Liver disease (chronic hepatitis or cirrhosis) or hepatic insufficiency
14. Chronic Obstructive Pulmonary Disease (COPD)
15. Cardiovascular disease
16. Diabetes mellitus
Increased cardiac output by 50% above the baseline without clinically significant abnormal findings on MUGA or echocardiography
life expectancy \>=6 months
Amenorrhea less than 1 year (less than 1 year after menopause) or premenopausal female with negative response to serum or urine pregnancy test before initiation of the treatment
Voluntary participants with written consent agreement for this study
You may not be if
The patients treated by other anti-cancer treatment except CHOP regimen or R (Rituximab)-CHOP regimen at 21 days interval
Pregnant or breast feeding woman, fertile woman without appropriate contraception
Patients with hypersensitivity against study drugs
Patients treated by other study medication or co-treatment with anticancer chemotherapy, hormone therapy, and immunotherapy
Clareo Health | Analysis of the Risk Factors for the Neutropenic Fever in the High Risk NHL Patients for Developing Febrile Neutropenia Who Received 3-weekly CHOP-like Chemotherapy With Primary G-CSF Prophylaxis; Prospective Multicenter Observation Study
